MERCER ISLAND, WA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)SEATTLE BIOMEDICAL RESEARCH INSTITUTE, founded in 1976, is a community nonprofit that reported $9.0M in total revenue in fiscal year 2018. Revenue fell 70% from the prior year — a significant decline worth monitoring. Expenses of $34.8M exceeded revenue, resulting in a 285% operating deficit.
WE CONDUCT FUNDAMENTAL INFECTIOUS DISEASE RESEARCH TO GENERATE CRITICAL NEW KNOWLEDGE ABOUT PATHOGENS AND THEIR INTERACTIONS WITH SEE SCHEDULE O FOR CONTINUATIONHUMANS TO ENABLE THE DISCOVERY AND DEVELOPMENT OF NOVEL INTERVENTIONS, RATIONAL VACCINES, THERAPEUTIC TARGETS, DRUGS AND DIAGNOSTICS. THESE DISEASES INCLUDE, BUT ARE NOT LIMITED TO, TUBERCULOSIS, MALARIA, AND HIV.WE ARE ALSO ENGAGED IN TRAINING THE NEXT GENERATION OF SCIENTISTS WHO WILL PERFORM SCIENTIFIC RESEARCH AND ADD CLINICAL CAPACITY THROUGHOUT THE WORLD.
WE CONDUCT FUNDAMENTAL INFECTIOUS DISEASE RESEARCH TO GENERATE CRITICAL NEW KNOWLEDGE ABOUT PATHOGENS AND THEIR INTERACTIONS WITH HUMANS TO ENABLE THE DISCOVERY AND DEVELOPMENT OF NOVEL...
WE CONDUCT FUNDAMENTAL INFECTIOUS DISEASE RESEARCH TO GENERATE CRITICAL NEW KNOWLEDGE ABOUT PATHOGENS AND THEIR INTERACTIONS WITH HUMANS TO ENABLE THE DISCOVERY AND DEVELOPMENT OF NOVEL INTERVENTIONS, RATIONAL VACCINES, THERAPEUTIC TARGETS, DRUGS AND DIAGNOSTICS. THESE DISEASES INCLUDE, BUT ARE NOT LIMITED TO, TUBERCULOSIS, MALARIA, AND HIV. WE ARE ALSO ENGAGED IN TRAINING THE NEXT GENERATION OF SCIENTISTS WHO WILL PERFORM SCIENTIFIC RESEARCH AND ADD CLINICAL CAPACITY THROUGHOUT THE WORLD.SEE SCHEDULE O FOR CONTINUATIONACCOMPLISHMENTS INCLUDE: -DISCOVERY OF RNA EDITING, WHICH PROVIDES A POTENTIAL BASIS FOR DRUG TREATMENTS FOR THREE MAJOR PARASITIC DISEASES.-IDENTIFICATION OF TWO HIV1 ENVELOPE ANTIGENS THAT ELICITED BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV WHEN INTRODUCED AS A TRIAL VACCINE IN PRIMATES.-GENETICALLY ENGINEERED THE MALARIA PARASITE P. FALCIPARUM BY THE PRECISE REMOVAL OF SPECIFIC GENES, CREATING A STRAIN THAT INFECTS HUMANS AND IS WELL TOLERATED BUT CANNOT CAUSE MALARIA, THUS MAKING IT A NOVEL NEW VACCINE CANDIDATE.
BIOQUEST: THE PRIMARY GOAL OF THE INSTITUTE'S SCIENCE OUTREACH PROGRAM, BIOQUEST, IS TO PROVIDE A CURRICULUM-RELEVANT, CAREER-INSPIRING, TECHNOLOGY-RICH SCIENCE EDUCATION PROGRAM WITHIN THE CONTEXT...
BIOQUEST: THE PRIMARY GOAL OF THE INSTITUTE'S SCIENCE OUTREACH PROGRAM, BIOQUEST, IS TO PROVIDE A CURRICULUM-RELEVANT, CAREER-INSPIRING, TECHNOLOGY-RICH SCIENCE EDUCATION PROGRAM WITHIN THE CONTEXT OF INFECTIOUS DISEASE RESEARCH TO HIGH SCHOOL STUDENTS, TEACHERS, AND THE GENERAL PUBLIC. WE ARE THE ONLY ORGANIZATION IN THE NATION TO OFFER A 32-PERSON TEACHING LAB, WITHIN THE FOOTPRINT OF AN INFECTIOUS DISEASE RESEARCH INSTITUTE.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2018 | 2017 | Change | |
|---|---|---|---|
| Revenue | $9,034,127 | $30,303,833 | -0.7% |
| Expenses | $34,810,558 | $34,217,943 | +0.0% |
| Net Income | $-25,776,431 | $-3,914,110 | +5.6% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| IRWIN GOVERMAN | CHAIR | 3.00 |
Officer
Director
|
$0 | $0 | $0 |
| KEVIN KELLY | VICE CHAIR | 3.00 |
Officer
Director
|
$0 | $0 | $0 |
| GREGG BLODGETT | TREASURER | 3.00 |
Officer
Director
|
$0 | $0 | $0 |
| STEVEN CLIFFORD | SECRETARY | 3.00 |
Officer
Director
|
$0 | $0 | $0 |
| ROSEMARY ARAGON | TRUSTEE | 3.00 |
Director
|
$0 | $0 | $0 |
| MARK ASHIDA | TRUSTEE | 3.00 |
Director
|
$0 | $0 | $0 |
| PERRY ATKINS | TRUSTEE | 3.00 |
Director
|
$0 | $0 | $0 |
| PATRICE AULD | TRUSTEE | 3.00 |
Director
|
$0 | $0 | $0 |
| DAVID GOESLING | TRUSTEE | 3.00 |
Director
|
$0 | $0 | $0 |
| ALAN LEVY | TRUSTEE | 3.00 |
Director
|
$0 | $0 | $0 |
| TREVER MOODY | TRUSTEE | 3.00 |
Director
|
$0 | $0 | $0 |
| BRIAN OLSAVSKY | TRUSTEE | 3.00 |
Director
|
$0 | $0 | $0 |
| TJ PETRIZZO | TRUSTEE | 3.00 |
Director
|
$0 | $0 | $0 |
| MARK MATHEWSON | TRUSTEE | 3.00 |
Director
|
$0 | $0 | $0 |
| BRIAN SCHWARTZ | TRUSTEE | 3.00 |
Director
|
$0 | $0 | $0 |
| DAVID STEWART | TRUSTEE | 3.00 |
Director
|
$0 | $0 | $0 |
| ROB THOMAS | TRUSTEE | 3.00 |
Director
|
$0 | $0 | $0 |
| KEN STUART | TRUSTEE/FOUNDER | 40.00 |
Officer
Director
|
$328,140 | $28,317 | $356,457 |
| JOHN AITCHISON | PRESIDENT | 40.00 |
Officer
|
$578,347 | $31,852 | $610,199 |
| STEFAN KAPPE | VP STRATEGIC DEVELOPMENT | 40.00 |
Officer
|
$249,997 | $27,251 | $277,248 |
| DAVID KEOGH | CHIEF OPERATING OFFICER | 40.00 |
Officer
|
$405,935 | $29,838 | $435,773 |
| DAVID SHERMAN | ASSOCIATE DIRECTOR | 40.00 |
Officer
|
$177,601 | $22,285 | $199,886 |
| ALAN ADEREM | PRESIDENT EMERITUS | 40.00 |
Highest
|
$497,467 | $35,705 | $533,172 |
| RONALD HOOD | SR DIRECTOR IT | 40.00 |
Highest
|
$234,845 | $16,127 | $250,972 |
| KENT IRWIN | SR DIR OPERATIONS/FACILITIES | 40.00 |
Highest
|
$194,382 | $15,265 | $209,647 |
| JANE M MILLS | LEGAL COUNSEL | 40.00 |
Highest
|
$184,847 | $15,354 | $200,201 |
| RANDELL WATKINS | SR FACILITIES MGR | 40.00 |
Highest
|
$180,848 | $7,738 | $188,586 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2019 | $9,034,127 | $34,810,558 | No data | $-25,776,431 |
| 2018 | $30,303,833 | $34,217,943 | $33,632,197 | $-3,914,110 |
Compare SEATTLE BIOMEDICAL RESEARCH INSTITUTE with other nonprofits in Washington and across the country.